Amid the global shortage of prostate cancer drug Lupron, AbbVie took its partner Takeda to court over alleged failures to live up to supply agreements. Now, a court has denied the company's plea to ...
China will become a global model for research and development innovation within the next five years, a senior executive of Japanese pharmaceutical company Takeda said during a recent media interview ...
Takeda has begun workforce reductions in the U.S. as the company aims to save more than 200 billion Japanese yen ($1.26 billion) in annual costs. About 634 roles assigned to the company’s U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results